Europe Pharmaceuticals Market Analysis and Forecast by Size, Share, Growth, Trends 2031
Europe Pharmaceuticals Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Molecule Type (Small Molecule and Biological and Biosimilar Products), Indication (Metabolic Diseases, Cancer, Immunology, Respiratory Disorder, Cardiovascular Disorder, Neurology Disorder, Rare Disease, and Others), Product (Branded and Generic), Type (Prescription and OTC Drugs), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
- Status : Published
- Report Code : TIPRE00041985
- Category : Life Sciences
- No. of Pages : 287
- Available Report Formats :
The Europe Pharmaceuticals Market size is expected to reach US$ 446.9 Billion by 2031 from US$ 317.3 Billion in 2024. The market is estimated to record a CAGR of 5.0% from 2025 to 2031.
Executive Summary and Europe Pharmaceuticals Market Analysis:The Europe pharmaceuticals market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The market growth is attributed to advanced healthcare infrastructure and increasing investments in research and development. Europe is home to leading pharmaceutical companies and biotech firms focused on innovative pharmaceutical products for a range of diseases, including cancer. The increasing prevalence of chronic diseases and the growing awareness of personalized medicine further fuel the demand for pharmaceuticals in Europe. As per WHO, in July 2024, diabetes was one of the most common chronic conditions in Europe, with ~64 Billion adults and nearly 300,000 children and adolescents having diabetes in the WHO European Region. WHO estimated that 1 in 3 people having diabetes are undiagnosed, and up to half may not meet their treatment targets in the region. As populations age and risk factors such as obesity increase, 1 in 10 Europeans may have diabetes by 2045. Europe has the highest burden of type 1 diabetes globally. As per WHO, in 2022, there were 4,471,422 new cases of cancer and 1,986,093 deaths due to cancer in Europe.
The market is expected to continue growing, with advancements in immunotherapies and the potential for new vaccine technologies offering promising opportunities for expansion across Europe. The Europe Pharmaceuticals Market is one of the largest and most dynamic markets globally, driven by various factors such as aging populations, increasing demand for innovative treatments, and regulatory advancements.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Europe Pharmaceuticals Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- By Molecule Type, the Europe Pharmaceuticals Market is segmented into Small Molecule and Biological and Biosimilar Products. Small Molecule held the largest share of the market in 2024.
- By Indication, the Europe Pharmaceuticals Market is segmented into Metabolic Diseases, Cancer, Immunology, Respiratory Disorder, Cardiovascular Disorder, Neurology Disorder, Rare Disease, and Others. Cancer held the largest share of the market in 2024.
- By Product, the Europe Pharmaceuticals Market is segmented into Branded and Generic. Branded held the largest share of the market in 2024.
- By Type, the Europe Pharmaceuticals Market is segmented into Prescription and OTC Drugs. Prescription held the largest share of the market in 2024.
- By Distribution Channel, the Europe Pharmaceuticals Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies held the largest share of the market in 2024.
The Pharmaceuticals Market presents substantial opportunities across multiple dimensions, driven by strong manufacturing capabilities, market expansion potential, technological advancements, economic contributions, and AI-driven innovations. In addition to geographical expansion, the pharmaceutical industry is witnessing a technological revolution, with significant advancements in gene therapy, preventive medicine, and digital health technologies. These innovations open the door for biotech firms, AI-driven drug discovery, and personalized medicine, which are expected to transform patient care, disease prevention, and treatment methodologies. The sector's economic significance is also remarkable, as the global pharmaceutical industry supports 74.3 Billion jobs, with 45.1 Billion indirect jobs in related industries and 23.7 Billion in other induced sectors. This underscores opportunities for investment in talent development, workforce expansion, and supply chain optimization, further driving economic growth.
Moreover, AI is reshaping pharmaceutical manufacturing and R&D, bringing efficiency and cost savings. AI-driven solutions can reduce labor costs by 10-30%, enhance machine and process efficiency by 10-35%, improve maintenance/service operations by 20-40%, and optimize logistics and routing by 20-40%. Additionally, AI is revolutionizing drug discovery, shortening timelines from discovery to preclinical candidate stages by up to 50%, leading to faster, more effective drug development. This provides a compelling opportunity for pharmaceutical companies to invest in AI, automation, and smart factories, enabling cost-efficient, high-quality drug production.
As a whole, the pharmaceutical sector offers significant growth opportunities through geographic expansion, digital transformation, AI adoption, and workforce development. Companies that leverage these trends-by investing in advanced technologies, forming strategic partnerships, and optimizing operations-will be well-positioned to drive innovation, efficiency, and profitability in the evolving global pharmaceutical landscape.
Europe Pharmaceuticals Market Country InsightsBy country, the Europe Pharmaceuticals Market is segmented into the United Kingdom, Germany, France, Italy, Spain, and the Rest of Europe. The Rest of Europe held the largest share in 2024.
Norway, Denmark, Sweden, Poland, Switzerland, Ukraine, Romania, Belgium, and the Czech Republic are among the major countries contributing to the growth of the pharmaceuticals market in the Rest of Europe. The market in these countries is characterized by strong healthcare infrastructure, substantial investment in biotechnology, and a collaborative approach to research. The Netherlands and Belgium, both central to the European Union's healthcare landscape, are also witnessing rapid advancements in pharmaceutical research.
Further, the increasing prevalence of chronic diseases in the Rest of Europe is likely to boost the demand for pharmaceuticals. As per Eurostat, among the EU countries, the share of deaths from cancer in the total number of deaths in 2021 exceeded 26.0% in Denmark (28.2%), Ireland (27.7%), Slovenia (27.1%) and the Netherlands (26.6%). The number of new cancer cases in Denmark, Ireland, Slovenia, and the Netherlands was 48,840; 31,242; 14,402; and 132,319, respectively. Additionally, AstriVax Therapeutics (Belgium), a clinical-stage biopharmaceutical company established in 2022, is dedicated to pioneering DNA-based immunotherapies through an innovative technology platform. Its mission is to tackle some of the most challenging diseases, with a primary emphasis on treating Hepatitis B, HPV, and other emerging infections. Currently, AstriVax Therapeutics is developing AVX70371, a therapeutic vaccine candidate for chronic Hepatitis B that effectively stimulates the production of specific CD4+ and CD8+ T-cells.
Europe Pharmaceuticals Market Company ProfilesSome of the key players operating in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Viatris Inc, Sanofi SA, Bristol-Myers Squibb Co, Johnson & Johnson, AstraZeneca Plc, AbbVie Inc, Eli Lilly and Co, Hikma Pharmaceuticals Plc, UCB SA, and ESTEVE.
These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
Europe Pharmaceuticals Market Research MethodologyThe following methodology has been followed for the collection and analysis of data presented in this report:
Secondary Research
The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Company websites,
annual reports, financial statements, broker analyses, and investor presentationsIndustry trade journals
and other relevant publicationsGovernment documents,
statistical databases, and market reportsNews articles,
press releases, and webcasts specific to companies operating in the market
Note:
All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.Primary Research
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:
- Validate and refine findings from secondary research
- Enhance the expertise and market understanding of the analysis team
- Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
Industry stakeholders:
Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales ManagersExternal experts:
Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
3.3 Assumptions and Limitations
4. Pharmaceutical Market Landscape
4.1 PEST Analysis
4.2 Regulatory Landscape
4.2.1 Europe
4.3 List of Key Suppliers:
4.4 Average selling Price:
4.5 Sourcing Strategy:
4.6 Market Entry Barriers in the Global Pharmaceutical Market:
4.7 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:
5. Europe Pharmaceutical Market – Key Market Dynamics
5.1 Europe Pharmaceutical Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Global Disease Burden and Increasing Demand for Innovative Treatments
5.2.2 Expanding Global Access to Medicines and Growing Emerging Markets
5.3 Market Restraints
5.3.1 Regulatory Pressures and Market Shifts
5.4 Market Opportunities
5.4.1 Harnessing Innovation, AI, and Market Expansion
5.5 Future Trends
5.5.1 Regional Power Shifts, Supply Chain Diversification, and Regulatory Evolution
5.6 Impact of Drivers and Restraints:
6. Pharmaceutical Market – Europe Analysis
6.1 Europe Pharmaceutical Market Revenue (US$ Billion), 2021–2031
6.2 Europe Pharmaceutical Market Forecast Analysis
7. Europe Pharmaceutical Market Analysis – by Molecule Type
7.1 Small Molecule
7.1.1 Overview
7.1.2 Small Molecule: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.2 Biological and Biosimilar Products
7.2.1 Overview
7.2.2 Biological and Biosimilar Products: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8. Europe Pharmaceutical Market Analysis – by Indication
8.1 Metabolic Diseases
8.1.1 Overview
8.1.2 Metabolic Diseases: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.2 Cancer
8.2.1 Overview
8.2.2 Cancer: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.3 Immunology
8.3.1 Overview
8.3.2 Immunology: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.4 Respiratory Disorder
8.4.1 Overview
8.4.2 Respiratory Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.5 Cardiovascular Disorder
8.5.1 Overview
8.5.2 Cardiovascular Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.6 Neurology Disorder
8.6.1 Overview
8.6.2 Neurology Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.7 Rare Disease
8.7.1 Overview
8.7.2 Rare Disease: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.8 Others
8.8.1 Overview
8.8.2 Others: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9. Europe Pharmaceutical Market Analysis – by Product
9.1 Branded
9.1.1 Overview
9.1.2 Branded: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9.2 Generic
9.2.1 Overview
9.2.2 Generic: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10. Europe Pharmaceutical Market Analysis – by Type
10.1 Prescription
10.1.1 Overview
10.1.2 Prescription: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10.2 OTC Drugs
10.2.1 Overview
10.2.2 OTC Drugs: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11. Europe Pharmaceutical Market Analysis – by Distribution Channel
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12. Europe Pharmaceutical Market – Country Analysis
12.1 Europe
12.1.1 Europe Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.1 Europe Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.2 United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.2.1 United Kingdom: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.2.2 United Kingdom: Europe Pharmaceutical Market Share – by Indication
12.1.1.2.3 United Kingdom: Europe Pharmaceutical Market Share – by Product
12.1.1.2.4 United Kingdom: Europe Pharmaceutical Market Share – by Type
12.1.1.2.5 United Kingdom: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.3 Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.3.1 Germany: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.3.2 Germany: Europe Pharmaceutical Market Share – by Indication
12.1.1.3.3 Germany: Europe Pharmaceutical Market Share – by Product
12.1.1.3.4 Germany: Europe Pharmaceutical Market Share – by Type
12.1.1.3.5 Germany: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.4 France: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.4.1 France: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.4.2 France: Europe Pharmaceutical Market Share – by Indication
12.1.1.4.3 France: Europe Pharmaceutical Market Share – by Product
12.1.1.4.4 France: Europe Pharmaceutical Market Share – by Type
12.1.1.4.5 France: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.5 Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.5.1 Italy: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.5.2 Italy: Europe Pharmaceutical Market Share – by Indication
12.1.1.5.3 Italy: Europe Pharmaceutical Market Share – by Product
12.1.1.5.4 Italy: Europe Pharmaceutical Market Share – by Type
12.1.1.5.5 Italy: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.6 Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.6.1 Spain: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.6.2 Spain: Europe Pharmaceutical Market Share – by Indication
12.1.1.6.3 Spain: Europe Pharmaceutical Market Share – by Product
12.1.1.6.4 Spain: Europe Pharmaceutical Market Share – by Type
12.1.1.6.5 Spain: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.7 Switzerland: Pharmaceutical Market – Revenue, 2021 - 2031 (US$ Billion)
12.1.1.7.1 Switzerland: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.7.2 Switzerland: Europe Pharmaceutical Market Share – by Indication
12.1.1.7.3 Switzerland: Europe Pharmaceutical Market Share – by Product
12.1.1.7.4 Switzerland: Europe Pharmaceutical Market Share – by Type
12.1.1.7.5 Switzerland: Europe Pharmaceutical Market Share – by Distribution Channel
12.1.1.8 Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.8.1 Rest of Europe: Europe Pharmaceutical Market Share – by Molecule Type
12.1.1.8.2 Rest of Europe: Europe Pharmaceutical Market Share – by Indication
12.1.1.8.3 Rest of Europe: Europe Pharmaceutical Market Share – by Product
12.1.1.8.4 Rest of Europe: Europe Pharmaceutical Market Share – by Type
12.1.1.8.5 Rest of Europe: Europe Pharmaceutical Market Share – by Distribution Channel
13. Competitive Landscape
13.1 Company Market Share Analysis
14. Industry Landscape
14.1 Overview
14.2 Expansion
14.3 New Product Development
14.4 Merger and Acquisition
14.5 Partnerships
14.6 Other Business Strategies
15. Company Profiles
15.1 Johnson & Johnson
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Pfizer Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Merck & Co Inc
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Eli Lilly and Co
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Financial Overview
15.4.4 SWOT Analysis
15.4.5 Key Developments
15.5 Bristol-Myers Squibb Co
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 ESTEVE
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 UCB SA
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Teva Pharmaceutical Industries Ltd
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Hikma Pharmaceuticals Plc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Viatris Inc
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 AstraZeneca Plc
15.11.1 1Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 Sanofi SA
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
15.13 GSK Plc
15.13.1 Key Facts
15.13.2 Business Description
15.13.3 Products and Services
15.13.4 Financial Overview
15.13.5 SWOT Analysis
15.13.6 Key Developments
15.14 F. Hoffmann-La Roche Ltd
15.14.1 Key Facts
15.14.2 Business Description
15.14.3 Products and Services
15.14.4 Financial Overview
15.14.5 SWOT Analysis
15.14.6 Key Developments
15.15 Novartis AG
15.15.1 Key Facts
15.15.2 Business Description
15.15.3 Products and Services
15.15.4 Financial Overview
15.15.5 SWOT Analysis
15.15.6 Key Developments
15.16 AbbVie Inc
15.16.1 Key Facts
15.16.2 Business Description
15.16.3 Products and Services
15.16.4 Financial Overview
15.16.5 SWOT Analysis
15.16.6 Key Developments
16. Appendix
16.1 Glossary of Terms
16.2 About The Insight Partners
List of Tables
Table 1. Europe Pharmaceutical Market Segmentation
Table 2. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Table 3. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Molecule Type
Table 4. Table: Top-Selling Drugs in 2021
Table 5. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Indication
Table 6. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Product
Table 7. Key brands facing patent expirations
Table 8. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Type
Table 9. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Distribution Channel
Table 10. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Country
Table 11. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 12. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 13. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 14. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 15. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 16. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 17. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 18. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 19. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 20. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 21. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 22. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 23. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 24. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 25. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 26. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 27. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 28. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 29. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 30. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 31. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 32. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 33. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 34. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 35. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 36. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 37. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 38. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 39. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 40. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 41. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 42. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 43. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 44. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 45. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 46. Company Market Share Analysis
Table 47. Glossary of Terms, Pharmaceutical Market
List of Figures
Figure 1. Europe Pharmaceutical Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Pharmaceutical Market Revenue (US$ Billion), 2021–2031
Figure 5. Europe Pharmaceutical Market Share (%) – by Molecule Type (2024 and 2031)
Figure 6. Small Molecule: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 7. Biological and Biosimilar Products: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 8. Europe Pharmaceutical Market Share (%) – by Indication (2024 and 2031)
Figure 9. Metabolic Diseases: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 10. Cancer: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 11. Immunology: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 12. Respiratory Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 13. Cardiovascular Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 14. Neurology Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 15. Rare Disease: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 16. Others: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 17. Europe Pharmaceutical Market Share (%) – by Product (2024 and 2031)
Figure 18. Branded: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 19. Generic: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 20. Europe Pharmaceutical Market Share (%) – by Type (2024 and 2031)
Figure 21. Prescription: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 22. OTC Drugs: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 23. Europe Pharmaceutical Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 24. Hospital Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 25. Retail Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 26. Online Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 27. Europe Pharmaceutical Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 28. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 29. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 30. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 31. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 32. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 33. Switzerland: Pharmaceutical Market – Revenue, 2021 - 2031 (US$ Billion)
Figure 34. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For